Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Evoke Pharma ( (EVOK) ) just unveiled an announcement.
Evoke Pharma, Inc. has appointed Benjamin Smeal as a Class II director with a term expiring at the 2027 annual meeting. Smeal, a seasoned investor with a background in public equities and hedge funds, will serve on key committees, bringing valuable expertise to the board. As part of the non-employee director compensation program, he receives stock options and cash compensation, enhancing the company’s strategic direction and governance.
Learn more about EVOK stock on TipRanks’ Stock Analysis page.
